Aurigene Pharmaceutical Services Limited is a leading contract research, development, and manufacturing organization (CRO/CDMO) and a long-term partner providing end-to-end solutions thereby accelerating innovation. With a strong legacy of services in discovery chemistry, discovery biology, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide by providing truly integrated services.
We handle both small molecule and large-molecule services across various complex technology platforms and niche technologies. We have access to FDA-inspected dedicated R and D centers in India and cGMP sites across India, UK and Mexico. Beyond science, our operations are rooted in the fundamental principles of compliance, information security, quality and sustainability.
Read more about our infrastructure to see how we are positioned to provide end-to-end services:
“ I’m very satisfied with the chemistry work at Aurigene, collaborated both chemistry (FTE) and biology (FFS). Technical discussion, weekly updates and meetings were good.”Testimonial By Biotech, US
“Aurigene is very flexible in allocating FTEs and shipping compounds to the preferred destination. Updates on raw material, reports and LNBs are remarkable. Quick turn around time for solving problems using analytical techniques.”Testimonial By Large Pharma, APAC
“Based on the FFS experience with Aurigene, it increased the bandwidth from FFS to FTE business. The level of communication and transparency in communication was excellent. Project reports and weekly updates are prepared well and on time. ”Testimonial By Biotech, US
“Based on the pilot peptide program, we extended an FTE collaboration with Aurigene. The scientific team was excellent in communication and problem-solving. The management was proactive and ready to invest in capability and capacity building.”Testimonial By Large pharma, US
“Happy with the quality of product, productivity and problem-solving capacity. Proactive communication about shipments helped us to plan our studies efficiently. Aurigene is a one-stop-shop for our discovery and development needs.”Testimonial By Large pharma, EU
“Happy with the scientific team, hence restarted research collaboration. The team is very responsible, trustable, and reliable. All discovery services are under one roof.”Testimonial By Biotech, US
SEPTEMBER 04, 2023
Discover the Opportunities: Visit Aurigene Pharmaceutical Services at CPHI BarcelonaThe Contract Research, Development and Manufacturing Organization (CRDMO) industry is a dynamic and rapidly evolving sector emerging as it plays a vital role in providing a wide range of services enabling drug companies to bring their products to market efficiently and effectively...Read More
With more than 200 distinct cancer types recognized and steady increase in cancer incidence rates, the fight with cancer takes a new shape with each emerging decade. First was surgery, followed by radiotherapy and chemotherapy. The fourth one was targeted cancer therapeutics, also known as precision therapies. Precision therapies were established with the discove...Read More
Objective & Challenges: Objective was to identify an optimized anti-bacterial lead molecule with in vivo efficacy in relevant infection models an acceptable safety profile, and a patentable series. Challenge was to develop a more efficacious compound than the reference standard.Study design: Compounds were designed and synth...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis . It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization . IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.